journal article·2019-12-04Open access

Semisynthetic supra plasma expanders: a new class of therapeutics to improve microcircualtion in sickle cell anaemia

Fantao Meng, Dhananjaya Kaul, Sangeetha Thangaswamy, Savita Bhutoria, Gary Gerfen, Craig Branch, Marcos Intaglietta, Seetharama A. Acharya

Abstract

Compromised microcirculation and endothelial dysfunction are hallmarks of sickle cell disease (SCD). EAF PEG Haemoglobin (Hb) and EAF PEG Albumin (Alb) represent a novel class of semisynthetic colloidal supra plasma expanders that improve microcirculation. The therapeutic activity of supra plasma expanders to attenuate vaso-occlusion and restore the haemodynamic functions in patients with SCD has been investigated using NY1DD, a transgenic mouse model of mild SCD without anaemia. Vaso-occlusion and perturbation of haemodynamics are amplified in NY1DD by hypoxia-reoxygenation protocol. EAF P5K6 Alb and Alb T12 (Alb conjugated with 12 copies of antioxidant tempo) attenuate vaso-occlusion when infused at the start of reoxygenation. However, only EAF PEG Alb restores haemodynamics close to levels in control C57BL. EAF P5K6 Alb-T12, active plasma expander conjugated with antioxidant, completely clears vaso-occlusion and restores normal haemodynamics. EAF PEG Hb also completely clears vaso-occlusion and restores normal haemodynamics. Pretreating NY1DD with EAF PEG Hb protects it from hypoxia reoxygenation-induced damages. EAF P5K6 Alb T12 attenuates the endothelial dysfunction in S + S Antilles mice as reflected by the vasodilatory response of its arteries and arterioles to vaso-dilators. Active plasma expanders are novel therapeutics to restore normal haemodynamics in SCD patients to improve tissue oxygenation during episodes of painful vaso-occlusive crisis. Abbreviations: 2-IT: 2-immothiolane; Mal-T: 4-Maleimido tempo; Alb: human serum albumin (HSA); Alb-T12: human albumin conjugated with 12 copies of tempo; EAF: extension arm facilitated; EAF PEG Hb: extension arm facilitated PEGylated haemoglobin; EAF PEG Alb: extension arm facilitated PEGylated albumin; EAF P3K6 Hb: extension arm facilitated PEGylated haemoglobin conjugated with 6 copies of PEG3K; EAF P5K6 Alb T12: extension arm facilitated PEGylated albumin conjugated with 6 copies of PEG5K and 12 copies of tempo; Hb: haemoglobin; HAS: human serum albumin (Alb); PEG: polyethylene glycol; MP4: MalPEG Hb, is formulated at 4.2 g/dL in lactated Ringer's solution, a product of Sangart; SCD: sickle cell disease; NO: nitric oxide; SEC: size exclusive chromatography; Vrbc: red cell velocity; Q: volumetric flow rates, Q; SNP: sodium nitroprusside.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hemoglobinopathies and Related Disorders · Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medicine, Albert Einstein College of Medicine

Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration

Department of Physiology and Biophysics, Albert Einstein College of Medicine

Department of Radiology, Albert Einstein College of Medicine

Department of Bioengineering, University of California

Funding

Royalty Funds to ASA

References (36)

Show source-provided references
1. Dieterich HJ. Recent developments in European colloid solutions. J Trauma. 2003;54:S26–S30.
2. 10.1007/s00134-004-2415-110.1007/s00134-004-2415-1 ↗
3. 10.1152/japplphysiol.00404.200410.1152/japplphysiol.00404.2004 ↗
4. 10.1042/CS2004000110.1042/CS20040001 ↗
5. 10.1152/ajpheart.00225.200510.1152/ajpheart.00225.2005 ↗
6. 10.1186/cc687410.1186/cc6874 ↗
7. 10.1152/ajpheart.01090.201110.1152/ajpheart.01090.2011 ↗
8. 10.2174/09298671179565611710.2174/092986711795656117 ↗
9. 10.1517/1465656080251987810.1517/14656560802519878 ↗
10. 10.1111/j.1440-1681.2007.04639.x10.1111/j.1440-1681.2007.04639.x ↗
11. 10.1111/j.1525-1594.2004.07392.x10.1111/j.1525-1594.2004.07392.x ↗
12. Hsai CJ. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules. United State patent 5 840 701 1998.
13. Manjula BN, Acharya AS. In: Nagel, R. L. editors. Methods in molecular medicine: hemoglobin disorders: molecular methods and protocols. Vol. 82, Totowa (NJ): Humana Press; 2003. p. 31–47.
14. 10.1021/bc020073310.1021/bc0200733 ↗
15. 10.1007/s10930-005-7837-210.1007/s10930-005-7837-2 ↗
16. 10.1021/bc700387810.1021/bc7003878 ↗
17. 10.1016/0026-2862(73)90054-X10.1016/0026-2862(73)90054-X ↗
18. 10.1172/JCI11835510.1172/JCI118355 ↗
19. 10.1016/0026-2862(74)90002-810.1016/0026-2862(74)90002-8 ↗
20. 10.1152/jappl.1967.22.2.33310.1152/jappl.1967.22.2.333 ↗
21. 10.1016/0026-2862(74)90043-010.1016/0026-2862(74)90043-0 ↗
22. 10.1016/0026-2862(80)90050-310.1016/0026-2862(80)90050-3 ↗
23. 10.1172/JCI922510.1172/JCI9225 ↗
24. 10.1152/ajpheart.01150.200310.1152/ajpheart.01150.2003 ↗
25. 10.1016/S0301-4622(97)00079-310.1016/S0301-4622(97)00079-3 ↗
26. 10.1152/jappl.1997.82.6.199510.1152/jappl.1997.82.6.1995 ↗
27. 10.1681/ASN.201110101910.1681/ASN.2011101019 ↗
28. 10.1007/978-3-642-40717-8_1110.1007/978-3-642-40717-8_11 ↗
29. 10.2174/1389200211314999001110.2174/13892002113149990011 ↗
30. Tasi AG, Cabrales P, Young MK, et al. Microvascular response to cell free Hb infusion in transgenic mouse model of sickle cell anemia. FASEB J. 2009;23(Suppl. 1).
31. 10.2174/187220831120603020010.2174/1872208311206030200 ↗
32. 10.1182/blood-2013-02-48628210.1182/blood-2013-02-486282 ↗
33. 10.1038/bjp.2008.21910.1038/bjp.2008.219 ↗
34. 10.3109/10731199.2010.48863510.3109/10731199.2010.488635 ↗
35. 10.3109/21691401.2012.76237010.3109/21691401.2012.762370 ↗
36. 10.1152/japplphysiol.01079.201210.1152/japplphysiol.01079.2012 ↗